362 related articles for article (PubMed ID: 1432103)
1. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism.
Chen HS; Lipton SA
J Physiol; 1997 Feb; 499 ( Pt 1)(Pt 1):27-46. PubMed ID: 9061638
[TBL] [Abstract][Full Text] [Related]
3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
[TBL] [Abstract][Full Text] [Related]
5. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
6. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
8. Trapping channel block of NMDA-activated responses by amantadine and memantine.
Blanpied TA; Boeckman FA; Aizenman E; Johnson JW
J Neurophysiol; 1997 Jan; 77(1):309-23. PubMed ID: 9120573
[TBL] [Abstract][Full Text] [Related]
9. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.
Parsons CG; Panchenko VA; Pinchenko VO; Tsyndrenko AY; Krishtal OA
Eur J Neurosci; 1996 Mar; 8(3):446-54. PubMed ID: 8963435
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention.
Müller WE; Pergande G; Ushijima H; Schleger C; Kelve M; Perovic S
Prog Mol Subcell Biol; 1996; 16():44-57. PubMed ID: 8822791
[TBL] [Abstract][Full Text] [Related]
12. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
13. Recovery of NMDA receptor currents from MK-801 blockade is accelerated by Mg2+ and memantine under conditions of agonist exposure.
McKay S; Bengtson CP; Bading H; Wyllie DJ; Hardingham GE
Neuropharmacology; 2013 Nov; 74():119-25. PubMed ID: 23402996
[TBL] [Abstract][Full Text] [Related]
14. Memantine selectively blocks extrasynaptic NMDA receptors in rat substantia nigra dopamine neurons.
Wu YN; Johnson SW
Brain Res; 2015 Apr; 1603():1-7. PubMed ID: 25656790
[TBL] [Abstract][Full Text] [Related]
15. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
Gilling KE; Jatzke C; Hechenberger M; Parsons CG
Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
[TBL] [Abstract][Full Text] [Related]
16. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine.
Weller M; Finiels-Marlier F; Paul SM
Brain Res; 1993 Jun; 613(1):143-8. PubMed ID: 8102306
[TBL] [Abstract][Full Text] [Related]
17. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
18. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta.
Giustizieri M; Cucchiaroni ML; Guatteo E; Bernardi G; Mercuri NB; Berretta N
J Pharmacol Exp Ther; 2007 Aug; 322(2):721-9. PubMed ID: 17496164
[TBL] [Abstract][Full Text] [Related]
19. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).
Parsons CG; Gruner R; Rozental J; Millar J; Lodge D
Neuropharmacology; 1993 Dec; 32(12):1337-50. PubMed ID: 8152525
[TBL] [Abstract][Full Text] [Related]
20. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells.
Bresink I; Benke TA; Collett VJ; Seal AJ; Parsons CG; Henley JM; Collingridge GL
Br J Pharmacol; 1996 Sep; 119(2):195-204. PubMed ID: 8886398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
